Victoria Wolodzko Smart, Senior Vice President at Mission at Susan G. Komen, shared a post on LinkedIn:
“Today, Susan G. Komen released our Breast Cancer 2026 Progress Outlook: New Research Discoveries and Opportunities.
New data shows the U.S. breast cancer death rate has declined 44% between its peak in 1989 and 2023 – averting an estimated 546,000 deaths due largely to advances in treatment and earlier detection through screening.
Yet breast cancer remains an urgent public health challenge. Incidence of invasive breast cancer has been rising since the mid-2000s, increasing by an average of 1% per year from 2013 to 2022, with faster growth among women under 50 (1.4% per year). An estimated 43,000 people in the U.S. are expected to die from the disease this year.
However, more promising advances for patients are on the way in 2026 thanks to the collective work of the scientific community and the patients who participate in every step of the research process. Three areas in particular are making significant progress for patients: new oral treatments for metastatic hormone receptor-positive breast cancer, simple blood tests that may be able to detect tiny traces of cancer DNA in the bloodstream and next-generation therapies that use lab-made antibodies to deliver chemotherapy directly to cancer cells.
Learn more about Komen’s research investments and the promise for the future.”
More posts featuring Victoria Wolodzko Smart